



## **ASX Announcement and Media Release**

**8 September, 2017**

**SciGen Ltd**

### **CHANGE IN CHIEF EXECUTIVE OFFICER AND THE BOARD OF DIRECTORS**

The Board of Directors of SciGen Limited (ASX: SIE) (“Company”) wishes to advise that it has on 8 September 2017, accepted the resignation of Mr. Ashley Morris, who has served as the Chief Executive Officer (“CEO”) and Executive Director of the Company.

The Board extends its best wishes to Mr. Morris, who resigned from both positions for personal reasons.

The Board is unanimous in its support to appoint Dr. Marek Dziki as CEO of the Company with effect from 8 September 2017.

Dr. Dziki has been a Non-Executive Director of the Company since 6 June 2016 and was appointed as the Chairman of the Board on 8 June 2016. He is a member of the Managing Board of Bioton S.A., overseeing all commercial operations.

Dr. Dziki has extensive experience in pharmaceuticals, chemicals, life science, bioscience, research & development and clinical research development. He established his career with Merck for 20 years and thereafter, in government institution relating to biopharma development and consultancy relating to disruptive innovation in new technology, emerging markets and financing.

In his capacity as CEO of the Company, Dr. Dziki does not receive remuneration from the Company.

### **APPOINTMENT OF EXECUTIVE DIRECTOR**

The Board is pleased to announce the appointment of Ms. Yvonne Lim Lean Guat as Executive Director of the Company with effect from 8 September 2017.

Ms. Lim, a Chartered Certified Accountant, is the Group Financial Controller and has been with the Company for 7 years. She started her career in Ernst & Young before joining Lafarge Group, the leader in building materials industry. Ms. Lim was in Lafarge Concrete Malaysia for almost 13 years, where she rose through the ranks to hold senior finance and accounting position.

## About SciGen Limited

SciGen Ltd (“SciGen”) is a biopharmaceutical company involved in sales and marketing of genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of endocrinology, paediatrics, neurology and oncology care.

Its core product portfolio consists of biosimilar products, notably, recombinant human insulin and recombinant human growth hormone which have undergone substantial clinical development. SciGen has since built a diversified portfolio in recent years, comprising neurology, oncology care products, paediatric supplements, orthopaedic injection therapy, anti-hypertensives and a range of medical devices.

SciGen has acquired the rights to distribute and market biopharmaceutical and proprietary products under both exclusive and semi-exclusive licensing arrangements. Its strategy is to focus on biosimilar products which have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen’s current focus is in the Asia Pacific region which provides growth opportunities for its range of products. Following a licensing agreement signed in early 2012, SciGen now has marketing rights for recombinant human insulin in the Middle East and Africa. SciGen’s contract manufacturer for recombinant human insulin is its ultimate holding company in Poland, Bioton S.A..

SciGen currently maintains internal sales and marketing teams at its subsidiary offices, whilst venturing into distribution partnerships in other markets. Through joint collaboration with its partners, SciGen uses its extensive expertise in regulatory and clinical environments, to cater to a broader spectrum of market.

SciGen was established in 1988, as a Singapore biopharmaceutical company. SciGen is listed on the Australian Stock Exchange (ASX code SIE). Its corporate headquarters is located in Singapore, with subsidiary offices in Australia, South Korea, China and a sales office in Philippines. Strategic distribution channels are present in Thailand, Hong Kong, Pakistan, Indonesia, Singapore, Bangladesh, Myanmar and Vietnam.

<b>For further information:</b> Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: <a href="mailto:gdunlop@scigen.com.au">gdunlop@scigen.com.au</a>	Adam Polonek SciGen Ltd +65 6779 6638